Evaluating leishmanicidal effects of Lucilia sericata products in combination with Apis mellifera honey using an in vitro model

Leishmaniasis is a zoonotic disease caused by an intracellular parasite from the genus Leishmania. Lack of safe and effective drugs has increasingly promoted researches into new drugs of natural origin to cure the disease. The study, therefore, aimed to investigate the anti-leishmanial effects of Lucilia sericata larval excretion/secretion (ES) in combination with Apis mellifera honey as a synergist on Leishmania major using an in vitro model. Various concentrations of honey and larval ES fractions were tested against promastigotes and intracellular amastigotes of L. major using macrophage J774A.1 cell line. The inhibitory effects and cytotoxicity of ES plus honey were evaluated using direct counting method and MTT assay. To assess the effects of larval ES plus honey on the amastigote form, the rate of macrophage infection and the number of amastigotes per infected macrophage cell were estimated. The 50% inhibitory concentration (IC50) values were 21.66 μg/ml, 43.25 60 μg/ml, 52.58 μg/ml, and 70.38 μg/ml for crude ES plus honey, ES >10 kDa plus honey, ES <10 kDa plus honey, and honey alone, respectively. The IC50 for positive control (glucantime) was 27.03 μg/ml. There was a significant difference between viability percentages of promastigotes exposed to different doses of applied treatments compared to the negative control (p≤ 0.0001). Microscopic examination of amastigote forms revealed that dosages applied at 150 to 300 μg/ml significantly reduced the rate of macrophage infection and the number of amastigotes per infected macrophage cell. Different doses of larval products plus honey did not show a significant toxic effect agaist macrophage J774 cells. The larval ES fractions of L. sericata in combination with A. mellifera honey acted synergistically against L. major.

[1]  F. Ghaffarifar,et al.  Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions , 2022, Parasites & Vectors.

[2]  M. Bakhtiyari,et al.  The leishmanicidal effect of Lucilia sericata larval saliva and hemolymph on in vitro Leishmania tropica , 2021, Parasites & vectors.

[3]  A. K. Mehata,et al.  Bradford assay as a high-throughput bioanalytical screening method for conforming pathophysiological state of the animal , 2020 .

[4]  M. Tahmasebi,et al.  A Survey on Inhibitory Effect of Whole-Body Extraction and Secretions of Lucilia sericata's Larvae on Leishmania major In vitro , 2020, Advanced biomedical research.

[5]  A. Khamesipour,et al.  Niosomal formulation of amphotericin B alone and in combination with glucantime: In vitro and in vivo leishmanicidal effects. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  M. Yaman,et al.  What is the best animal model for leishmaniasis studies , 2018 .

[7]  E. Coskunpinar,et al.  Regulation of MMP 2 and MMP 9 expressions modulated by AP-1 (c-jun) in wound healing: improving role of Lucilia sericata in diabetic rats , 2018, Acta Diabetologica.

[8]  M. Maleki,et al.  Effects of a Traditional Iranian Remedy on Cutaneous Leishmaniasis , 2018, Health Scope.

[9]  Mohammad Reza Aflatoonian,et al.  Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran , 2018, PloS one.

[10]  Mahdi Delavari,et al.  Chitosan-titanium dioxide-glucantime nanoassemblies effects on promastigote and amastigote of Leishmania major. , 2018, International journal of biological macromolecules.

[11]  F. Ghaffarifar,et al.  Therapeutic effects of Lucilia sericata larvae on cutaneous leishmaniasis wounds caused by Leishmania major using BALB/c mice as animal model , 2017 .

[12]  J. Cane,et al.  Survey of Hatching Spines of Bee Larvae Including Those of Apis mellifera (Hymenoptera: Apoidea) , 2017, Journal of insect science.

[13]  A. Amaral,et al.  Cytotoxicity and anti-Leishmania amazonensis activity of Citrus sinensis leaf extracts , 2017, Pharmaceutical biology.

[14]  F. Zahedifard,et al.  Leishmaniasis and various immunotherapeutic approaches , 2016, Parasitology.

[15]  M. Ayala,et al.  The effect of Lucilia sericata- and Sarconesiopsis magellanica-derived larval therapy on Leishmania panamensis. , 2016, Acta tropica.

[16]  A. Khamesipour,et al.  Anti Leishmania activity of Lucilia sericata and Calliphora vicina maggots in laboratory models. , 2016, Experimental parasitology.

[17]  M. Gouya,et al.  Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces , 2016 .

[18]  Wondemagegn Mulu,et al.  Challenges in visceral leishmaniasis control and elimination in the developing countries: A review. , 2016, Journal of vector borne diseases.

[19]  A. Saki,et al.  Epidemiological study of cutaneous leishmaniasis in southwest of Iran during 2001–2011 , 2016 .

[20]  Mostafa I. Hassan,et al.  ANTIMICROBIAL ACTIVITY FOR EXCRETION AND SECRETION OF THE GREENBOTTLE FLY LARVAE LUCILIA SERICATA (MEIGEN) (DIPTERA: CALLIPHORIDAE). , 2016, Journal of the Egyptian Society of Parasitology.

[21]  M. Patarroyo,et al.  The effects of Sarconesiopsis magellanica larvae (Diptera: Calliphoridae) excretions and secretions on fibroblasts. , 2015, Acta tropica.

[22]  M. Wainwright,et al.  An Initial In vitro Investigation into the Potential Therapeutic Use Of Lucilia sericata Maggot to Control Superficial Fungal Infections , 2013 .

[23]  A. Rehman,et al.  Mucocutaneous Leishmaniasis: Knowledge, Attitudes, and Practices Among Paraguayan Communities, Patients, and Health Professionals , 2013, Journal of tropical medicine.

[24]  M. Aslan,et al.  Detection of anti-leishmanial effect of the Lucilia sericata larval secretions in vitro and in vivo on Leishmania tropica: first work. , 2012, Experimental parasitology.

[25]  Nisha Singh,et al.  Leishmaniasis: current status of available drugs and new potential drug targets. , 2012, Asian Pacific journal of tropical medicine.

[26]  J. Cano,et al.  Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.

[27]  S. Habibi,et al.  Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis. , 2011, The Southeast Asian journal of tropical medicine and public health.

[28]  M. Nilforoushzadeh,et al.  Efficacy of Adding Topical Honey-Based Hydroalcoholic Extract Nigella Sativa 60% Compared to Honey Alone in Patients with Cutaneous Leishmaniasis Receiving Intralesional Glucantime , 2010 .

[29]  E. Cherniack Bugs as drugs, Part 1: Insects: the "new" alternative medicine for the 21st century? , 2010, Alternative medicine review : a journal of clinical therapeutic.

[30]  N. Namias,et al.  Biologic Dressing in Burns , 2008, The Journal of craniofacial surgery.

[31]  Milagros Oviedo,et al.  Evaluación preliminar en un modelo animal de la terapia con larvas de Lucilia sericata para el tratamiento de la leishmaniasis cutánea , 2008 .

[32]  J. Betts The clinical application of honey in wound care. , 2008, Nursing times.

[33]  M. Nilforoushzadeh,et al.  Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis , 2007, BMC complementary and alternative medicine.

[34]  V. Yardley,et al.  Current scenario of drug development for leishmaniasis. , 2006, The Indian journal of medical research.

[35]  R. Cooper,et al.  The antibacterial activity of honey against coagulase-negative staphylococci. , 2005, The Journal of antimicrobial chemotherapy.

[36]  D. C. Ayres,et al.  Effects of hyperbaric oxygen on Leishmania amazonensis promastigotes and amastigotes. , 2005, Parasitology international.

[37]  M. Ouellette,et al.  Leishmaniasis: drugs in the clinic, resistance and new developments. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[38]  Samuel A. Lee,et al.  Therapy of cutaneous leishmaniasis. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[39]  Cathy Buntting,et al.  The effect of dilution on the rate of hydrogen peroxide production in honey and its implications for wound healing. , 2003, Journal of alternative and complementary medicine.

[40]  P. Prete,et al.  Growth effects of Phaenicia sericata larval extracts on fibroblasts: mechanism for wound healing by maggot therapy. , 1997, Life sciences.

[41]  Zeina Bassam,et al.  The effects of honey on Leishmania parasites: an in vitro study. , 1997, Tropical doctor.

[42]  M. Sandholm,et al.  Antibacterial effect of the glucose oxidase-glucose system on food-poisoning organisms. , 1989, International journal of food microbiology.

[43]  F. Ghaffarifar,et al.  In vitro and in vivo effects of natural honey on Leishmania major. , 2022, Annals of parasitology.

[44]  F. Ghaffarifar,et al.  A study on the in vitro and in vivo effects of aqueous and alcoholic extracts of Salvia mirzayanii on Leishmania major. , 2021, Annals of parasitology.

[45]  M. Patarroyo,et al.  Evaluating the anti-leishmania activity of Lucilia sericata and Sarconesiopsis magellanica blowfly larval excretions/secretions in an in vitro model. , 2018, Acta tropica.

[46]  R. B. Pedroso,et al.  Leishmanicidal activity of synthetic chalcones in Leishmania (Viannia) braziliensis. , 2014, Experimental parasitology.

[47]  A. Shahzad,et al.  In vitro antiviral activity of honey against varicella zoster virus (VZV): A translational medicine study for potential remedy for shingles. , 2012, Translational biomedicine.

[48]  N. A. Segura,et al.  Lucilia sericata strain from Colombia: Experimental colonization, life tables and evaluation of two artificial diets of the blowfly Lucilia sericata (Meigen) (Diptera: Calliphoridae), Bogotá, Colombia strain. , 2010, Biological research.

[49]  R. Cooper Using honey to inhibit wound pathogens. , 2008, Nursing times.

[50]  M. Oviedo,et al.  [Preliminary evaluation of maggot (Diptera: Calliphoridae) therapy as a potential treatment for leishmaniasis ulcers]. , 2008, Biomedica : revista del Instituto Nacional de Salud.

[51]  P. Nibbering,et al.  # The Author(s) 2009. This article is published with open access at Springerlink.com M. J. A. van der Plas: M. Baldry: J. T. van Dissel: , 2022 .